Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection

PLoS Neglected Tropical Diseases

Volumn 10, Issue 4, 2016, Pages

  Arumugam, Sridhar ^a   Wei, Junfei ^b   Liu, Zhuyun ^b   Abraham, David ^c   Bell, Aaron ^d   Bottazzi, Maria Elena ^b   Hotez, Peter J ^b   Zhan, Bin ^b   Lustigman, Sara ^d   Klei, Thomas R ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BM 103 PROTEIN; BM RAL 2 PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; HELMINTH ANTIBODY; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE;

AMINO ACID SEQUENCE; ARTICLE; BRUGIAN FILARIASIS; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; GERBIL; HELMINTHIASIS; IMMUNE RESPONSE; IMMUNOELECTRON MICROSCOPY; LYMPHATIC FILARIASIS; MALE; NONHUMAN; ONCHOCERCIASIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE ALIGNMENT; VACCINATION; ANIMAL; BLOOD; BRUGIA MALAYI; DISEASE MODEL; FILARIASIS; GENETICS; IMMUNOLOGY; PARASITE LOAD; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; BRUGIA MALAYI; DISEASE MODELS, ANIMAL; FILARIASIS; GERBILLINAE; PARASITE LOAD; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84964838046     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004586     Document Type: Article

References (82)

1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386(9995): 743–800. doi: 10.1016/S0140-6736(15)60692-426063472
2. Hotez PJ, Bottazzi ME, Zhan B, Makepeace BL, Klei TR, Abraham D, et al. The Onchocerciasis Vaccine for Africa—TOVA—Initiative. PLoS Negl Trop Dis. 2015; 9(1): e0003422. doi: 10.1371/journal.pntd.000342225634641
3. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG, Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. PLoS Negl Trop Dis. 2013; 7(4): e2169. doi: 10.1371/journal.pntd.000216923634234
4. Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa?Bull. World Health Organ. 2002; 80: 384–391. 12077614
5. Eng JK, Prichard RK, A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated- and ivermectin-treated patients. Mol Biochem Parasitol. 2005; 142: 193–202. 15885823
6. Boatin BA, Richards FO, JrControl of onchocerciasis. Adv Parasitol.2006; 61: 349–394. 16735169
7. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK, Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007; 369: 2021–2029. 17574093
8. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK, . Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011; 5: e998. doi: 10.1371/journal.pntd.000099821468315
9. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997; 350: 18–22. 9217715
10. Kim YE, Remme JH, Steinmann P, Stolk WA, Roungou JB, Tediosi F, Control, Elimination, and Eradication of River Blindness: Scenarios, Timelines, and Ivermectin Treatment Needs in Africa. PLoS Negl Trop Dis. 2015; 9(4): e0003664. doi: 10.1371/journal.pntd.000366425860569
11. Keenan JD, Hotez PJ, Amza A, Stoller NE, Gaynor BD, Porco TC, et al. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. PLoS Negl Trop Dis. 2013; 7(12):e2562. doi: 10.1371/journal.pntd.000256224340111
12. Bottazzi ME, Miles AP, Diemert D, Hotez PJ, An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev Vaccines. 2006; 5: 189–198. 16608419
13. Prichard RK, Basáñez MG, Boatin BA, McCarthy JS, García HH, Yang GJ, et al. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis. 2012; 6(4): e1549. doi: 10.1371/journal.pntd.000154922545163
14. Lustigman S, Lamb T.J, Current approaches to the development of a vaccine against filarial nematodes. In: (Ed.), Immunity to Parasitic Infection. John Wiley & Sons, Ltd, Chichester, UK, 2012. pp. 459–470.
15. Lange AM, Yutanawiboonchai W, Lok JB, Trpis M, Abraham D, Induction of protective immunity against larval Onchocerca volvulus in a mouse model. Am J Trop Med Hyg. 1993; 49: 783–788. 8279644
16. Tchakoute VL, Graham SP, Jensen SA, Makepeace BL, Nfon CK, Njongmeta LM, et al. In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. Proc Natl Acad Sci USA. 2006; 103: 5971–5976. 16585501
17. Morris CP, Evans H, Larsen SE, Mitre E, A comprehensive, model-based review of vaccine and repeat infection trials for filariasis. Clin Microbiol Rev. 2013; 26(3): 381–421. doi: 10.1128/CMR.00002-1323824365
18. Lustigman S, Abraham D, Klei TR, Caffrey Conor R., Anti-filarial Vaccine Development: Present and Future Approaches. In: Parasitic Helminths: Targets, Screens, Drugs and Vaccines. First Edition. Edited by Wiley-VCH Verlag GmbH & Co. KGaA, 2012.
19. Hess JA, Zhan B, Bonne-Année S, Deckman JM, Bottazzi ME, Hotez PJ, et al. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol. 2014; 44(9): 637–646. doi: 10.1016/j.ijpara.2014.04.00624907553
20. Unnasch TR, Gallin MY, Soboslay PT, Erttmann KD, Greene BM, Isolation and characterization of expression cDNA clones encoding antigens of Onchocerca volvulus infective larvae."J Clin Invest. 1988; 82 (1): 262–269. 2455736
21. Bradley JE, Tuan RS, Shepley KJ, Tree TI, Maizels RM, Helm R, et al. Onchocerca volvulus: characterization of an immunodominant hypodermal antigen present in adult and larval parasites. Exp parasitol. 1993; 77(4): 414–424. 8253155
22. Lustigman S, Brotman B, Johnson EH, Smith AB, Huima T, Prince AM, Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface-associated antigen. Mol Biochem Parasitol. 1992; 50(1): 79–93. 1542318
23. Lizotte-Waniewski M, Tawe W, Guiliano DB, Lu W, Liu J, Williams SA, Lustigman S, Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of an Onchocerca volvulus larval cDNA library. Infect Immu. 2000; 68:3491–3501.
24. Lustigman S, Johnson E, Brotman B, Huima T, Prince AM, Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface associated antigen. Mol Biochem Parasitol. 1992; 50:79–94. 1542318
25. Goud GN, Zhan B, Ghosh K, Loukas A, Hawdon J, Dobardzic A, et al. Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum. J Infect Dis. 2004; 189: 919–929. 14976610
26. Zhan B, Hotez JP, Wang Y, Hawdon MJ, A developmentally regulated metalloprotease secreted by host-stimulated Ancylostoma caninum third-stage infective larvae is a member of the astacin family of protease. Mol Biochem Parasitol. 2002; 120: 291–296. 11897134
27. Asojo OA, Loukas A, Inan M, Barent R, Huang J, Plantz B, et al. Crystallization and preliminary X-ray analysis of Na-ASP-1, a multi-domain pathogenesis-related-1 protein from the human hookworm parasite Necator americanus. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005; 61: 391–394. 16511050
28. Klei TR, McVay CS, Dennis VA, Coleman SU, Enright FM, Casey HW, Brugia pahangi: Effects of duration of infection and parasite burden on lymphatic lesion severity, granulomatous hypersensitivity, and immune responses in jirds (Meriones unguiculatus). Exp Parasitol. 1990; 71: 393–4052226701
29. Thirugnanam S, Pandiaraja P, Ramaswamy K, Murugan V, Gnanasekar M, et al. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model. Exp Parasitol. 2007; 116(4): 483–491. 17442307
30. Vedi S, Dangi A, Hajela K, Misra-Bhattacharya S, Vaccination with 73kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. Vaccine. 2008; 26(47): 5997–6005. doi: 10.1016/j.vaccine.2008.08.07318817835
31. Vanam U, Pandey V, Prabhu PR, Dakshinamurthy G, Reddy MV, Kaliraj P, Evaluation of immunoprophylactic efficacy of Brugia malayi transglutaminase (BmTGA) in single and multiple antigen vaccination with BmALT-2 and BmTPX for human lymphatic filariasis. Am J Trop Med Hyg. 2009; 80(2): 319–324. 19190232
32. Shakya S, Singh PK, Kushwaha S, Misra-Bhattacharya S, . Adult Brugia malayi approximately 34 kDa (BMT-5) antigen offers Th1 mediated significant protection against infective larval challenge in Mastomys coucha. Parasitol Int. 2009; 58: 346–353. doi: 10.1016/j.parint.2009.07.00719638321
33. Dakshinamoorthy G, Samykutty AK, Munirathinam G, Shinde GB, Nutman T, Reddy MV, et al. Biochemical characterization and evaluation of a Brugia malayi small heat shock protein as a vaccine against lymphatic filariasis. PloS One. 2012; 7(4): e34077. doi: 10.1371/journal.pone.003407722496777
34. Kushwaha S, Singh PK, Rana AK, Misra-Bhattacharya S, Immunization of Mastomys coucha with Brugia malayi recombinant trehalose-6-phosphate phosphatase results in significant protection against homologous challenge infection. PloS One. 2013; 8(8): e72585doi: 10.1371/journal.pone.007258524015262
35. Dakshinamoorthy G, Kalyanasundaram R, Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation. Vaccine. 2013; 32(1): 19–25. doi: 10.1016/j.vaccine.2013.10.08324211167
36. Arumugam S, Wei J, Ward D, Abraham D, Lustigman S, Zhan B, et al. Vaccination with a genetically modified Brugia malayi cysteine protease inhibitor-2 reduces adult parasite numbers and affects the fertility of female worms following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. Int J Parasitol. 2014; 44(10): 675–679. doi: 10.1016/j.ijpara.2014.05.00324929131
37. Arumugam S, Zhan B, Abraham D, Ward D, Lustigman S, Klei TR, Vaccination with recombinant Brugia malayi cystatin proteins alters worm migration, homing and final niche selection following a subcutaneous challenge of Mongolian gerbils (Meriones unguiculatus) with B. malayi infective larvae. Parasit Vectors. 2014; 7(1): 43.
38. Knott J, The periodicity of the microfilaria of Wuchereria bancrofti. Preliminary report of some injection experiments. Trans R Soc Trop Med Hyg. 1935; 29: 59–64.
39. Melrose WD, Turner PF, Pisters P, Turner B, An improved Knott's concentration test for the detection of microfilariae. Trans R Soc Trop Med Hyg. 2000; 94(2): 176. 10897361
40. R Core TeamR: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2015. URL https://www.R-project.org/.
41. Canty A, Ripley B. Boot: Bootstrap R (S-Plus) Functions. R package version 1.3–17, 2015.
42. Davison AC, Hinkley DV, Bootstrap Methods and Their Applications. Cambridge University Press, Cambridge, 1997. ISBN 0-521-57391-2
43. Wong MM, Fredericks HJ, Ramachandran CP, Studies on immunization against Brugia malayi infection in the rhesus monkey. Bull World Health Organ. 1969; 40(4): 493–501. 4979899
44. Oothuman P, Denham DA, McGreevy PB, Nelson GS, Rogers R, Successful vaccination of cats against Brugia pahangi with larvae attenuated by irradiation with 10 krad cobalt 60. Parasite Immunol. 1979; 1(3): 209–216. 551378
45. Chusattayanond W, Denham DA, Attempted vaccination of jirds (Meriones unguiculatus) against Brugia pahangi with radiation attenuated infective larvae. J. Helminthol. 1986; 60(2): 149–155. 3734400
46. Ash LR, Riley JM, Development of subperiodic Brugia malayi in the jird, Meriones unguiculatus, with notes on infections in other rodents. J Parasitol. 1970; 56: 969–973. 5504534
47. Rathaur S, Yadav M, Gupta S, Anandharaman V, Reddy MV, Filarial glutathione-S-transferase: a potential vaccine candidate against lymphatic filariasis. Vaccine. 2008; 26(32): 4094–4100. doi: 10.1016/j.vaccine.2008.03.09918499308
48. Kalyanasundaram R, Balumuri P, Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds. Res Rep Trop Med. 2011; 2: 45–56.
49. Joseph SK, Sambanthamoorthy S, Dakshinamoorthy G, Munirathinam G, Ramaswamy K, Protective immune responses to biolistic DNA vaccination of Brugia malayi abundant larval transcript-2. Vaccine. 2012; 30(45): 6477–6482. doi: 10.1016/j.vaccine.2012.07.08422885273
50. Dakshinamoorthy G, Munirathinam G, Stoicescu K, Reddy MV, Kalyanasundaram R, Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis. PloS One. 2013; 8(10): e77394. doi: 10.1371/journal.pone.007739424146990
51. Dakshinamoorthy G, Samykutty AK, Munirathinam G, Reddy MV, Kalyanasundaram R, Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine. 2013; 31(12): 1616–1622. doi: 10.1016/j.vaccine.2012.09.05523036503
52. Veerapathran A, Dakshinamoorthy G, Gnanasekar M, Reddy MV, Kalyanasundaram R, Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Negl Trop Dis. 2009; 3(6): e457. doi: 10.1371/journal.pntd.000045719513102
53. Shrivastava N, Singh PK, Nag JK, Kushwaha S, Misra-Bhattacharya S, Immunization with a multisubunit vaccine considerably reduces establishment of infective larvae in a rodent model of Brugia malayi. Comp Immunol Microbiol Infect Dis. 2013; 36(5): 507–519. doi: 10.1016/j.cimid.2013.05.00323829972
54. Ah HS, Thompson PE, Brugia pahangi: infections and their effect on the lymphatic system of Mongolian jirds (Meriones unguiculatus). Exp Parasitol. 1973; 34(3): 393–411. 4773577
55. Chirgwin SR, Coleman SU, Porthouse KH, Klei TR, Tissue migration capability of larval and adult Brugia pahangi. J Parasitol. 2006; 92(1): 46–51. 16629314
56. Porthouse KH, Chirgwin SR, Coleman SU, Taylor HW, Klei TR, Inflammatory responses to migrating Brugia pahangi third-stage larvae. Infect Immun. 2006; 74(4): 2366–2372. 16552066
57. Nasarre C, Coleman SU, Rao U R, Klei TR. Brugia pahangi: Differential induction and regulation of jird inflammatory responses by life-cycles stages. Exp Parasitol. 1997; 87: 20–29. 9287954
58. Bosshardt SC, McCall JW, Coleman SU, Jones KL, Petit TA, Klei TR, Prophylactic activity of tetracycline against Brugia pahangi infection in jirds (Meriones unguiculatus). J Parasitol. 1993; 79(5): 775–777. 8410553
59. King CL, Kumaraswami V, Poindexter RW, Kumari S, Jayaraman K, Alling DW, et al. Immunologic tolerance in lymphatic filariasis. Diminished parasite-specific T and B lymphocyte precursor frequency in the microfilaremic state. J Clin Invest. 1992; 89(5): 1403–1410. 1569183
60. Petit TA, Coleman SU, Jones KL, Enright FM, Klei TR, Brugia pahangi: Effects of protective resistance on lymphatic lesions and granulomatous inflammation in infected jirds (Meriones unguiculatus). Exp Parasitol. 1993; 77(4): 395–404. 8253153
61. Anand SB, Kodumudi KN, Reddy MV, Kaliraj P, A combination of two Brugia malayi filarial vaccine candidate antigens (BmALT-2 and BmVAH) enhances immune responses and protection in jirds. J Helminthol. 2011; 85(4): 442–452. doi: 10.1017/S0022149X1000079921208482
62. Joseph SK, Ramaswamy K, Single multivalent vaccination boosted by trickle larval infection confers protection against experimental lymphatic filariasis. Vaccine. 2013; 31(33): 3320–3326. doi: 10.1016/j.vaccine.2013.05.07723735679
63. Shrivastava N, Singh PK, Nag JK, Kushwaha S, Misra-Bhattacharya S, Immunization with a multisubunit vaccine considerably reduces establishment of infective larvae in a rodent model of Brugia malayi. Comp. Immunol. Microbiol. Infect. Dis. 36(5), 507–519. doi: 10.1016/j.cimid.2013.05.00323829972
64. Dakshinamoorthy G, von Gegerfelt A, Andersen H, Lewis M, Kalyanasundaram R, Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model. PloS One. 2014; 9(11): e112982. doi: 10.1371/journal.pone.011298225401783
65. Schrempf‐Eppstein B, Kern A, Textor G, Lucius R, Acanthocheilonema viteae: vaccination with irradiated L3 induces resistance in three species of rodents (Meriones unguiculatus, Mastomys coucha, Mesocricetus auratus). Trop Med Int Health. 1977: 2(1), 104–110.
66. Turner HC, Walker M, Lustigman S, Taylor DW, Basáñez MG, Human onchocerciasis: modelling the potential long-term consequences of a vaccination programme. PLoS Negl Trop Dis. 2015: 9(7), p.e0003938. doi: 10.1371/journal.pntd.000393826186715
67. Hashmi S, Zhang J, Oksov Y, Ji Q, Lustigman S, The Caenorhabditis elegans CPI-2a cystatin-like inhibitor has an essential regulatory role during oogenesis and fertilization. J Biol Chem. 2006; 281(38): 28415–28429. 16857685
68. Zhang Z, Xu H, Gan W, Zeng S, Hu X, Schistosoma japonicum calcium-binding tegumental protein SjTP22.4 immunization confers praziquantel schistosomulumicide and antifecundity effect in mice. Vaccine. 2012: 30(34), 5141–5150. doi: 10.1016/j.vaccine.2012.05.05622683520
69. Fujiwara RT, Zhan B, Mendez S, Loukas A, Bueno LL, Wang Y, et al. Reduction of worm fecundity and canine host blood loss mediates protection against hookworm infection elicited by vaccination with recombinant Ac-16. Clin Vaccine Immunol. 2007: 14(3), 281–287. 17267592
70. Loukas A, Bethony JM, Williamson AL, Goud GN, Mendez S, Zhan B, et al. Vaccination of dogs with a recombinant cysteine protease from the intestine of canine hookworms diminishes the fecundity and growth of worms. J Infect Dis. 2004: 189(10), 1952–61. 15122534
71. Gregory WF, Atmadja AK, Allen JE, Maizels RM, The Abundant Larval Transcript-1 and-2 Genes of Brugia malayi Encode Stage-Specific Candidate Vaccine Antigens for Filariasis. Infect Immun. 2000; 68(7): 4174–4179. 10858234
72. Osborne J, Devaney E, The L3 of Brugia induces a Th2-polarized response following activation of an IL-4-producing CD4-CD8-alphabeta T cell population. Int Immunol. 1998; 10(10): 1583–1590. 9796925
73. Abraham D, Leon O, Schnyder-Candrian S, Wang CC, Galioto AM, Kerepesi LA, et al. Immunoglobulin E and eosinophil-dependent protective immunity to larval Onchocerca volvulus in mice immunized with irradiated larvae. Infect Immun. 2004; 72(2): 810–817. 14742524
74. Hartmann S, Sollwedel A, Hoffmann A, Sonnenburg B, Lucius R, Characterization of IgE responses in a rodent model of filariasis and the allergenic potential of filarial antigens using an in vitro assay. Parasite Immunol. 2003; 25: 9–16. 12753433
75. Baldwin CI, de Medeiros F, Denham DA, IgE responses in cats infected with Brugia pahangi. Parasite Immunol. 1993; 15: 291–296. 8332384
76. Hoffmann W, Petit G, Schulz-Key H, Taylor D, Bain O, Le Goff L, Litomosoides sigmodontis in mice: reappraisal of an old model for filarial research. Parasitol Today. 2000; 16(9): 387–389. 10951598
77. Petit G, Diagne M, Marechal P, Owen D, Taylor D, Bain O, Maturation of the filaria Litomosoides sigmodontis in BALB/c mice; comparative susceptibility of nine other inbred strains. Ann Parasitol Hum Comp. 1991; 67(5): 144–150.
78. Le Goff L, Lamb TJ, Graham AL, Harcus Y, Allen JE, IL-4 is required to prevent filarial nematode development in resistant but not susceptible strains of mice. Int J Parasitol. 2002; 32(10): 1277–1284. 12204227
79. Martin C, Le Goff L, Ungeheuer MN, Vuong PN, Bain O, Drastic reduction of a filarial infection in eosinophilic interleukin-5 transgenic mice. Infect Immun. 2000; 68(6): 3651–3656. 10816524
80. Goff LL, Maréchal P, Petit G, Taylor DW, Hoffmann W, Bain O, Early reduction of the challenge recovery rate following immunization with irradiated infective larvae in a filaria mouse system. Am J Trop Med Hyg. 1997; 2(12): 1170–1174.
81. Chirgwin SR, Elzer PH, Coleman SU, Nowling JM, Hagius SD, Edmonds MD, Klei TR, . Infection outcome and cytokine gene expression in Brugia pahangi-infected gerbils (Meriones unguiculatus) sensitized with Brucella abortus. Infect Immun. 2002: 70(11), 5938–5945. 12379668
82. Makepeace BL, Babayan SA, Lustigman S, Taylor DW, The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa. Expert Rev Vaccines. 2015: 1–3.